UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---------------

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February ~~December 31~~14, ~~2010~~2011

---------------

LAXAI PHARMA, LTD.

---------------------------------------

(Exact name of Registrant as specified in charter)


Israel	0-17788	N/A
(State of Incorporation)	(Commission File No.)	(IRS Employer
		Identification Number)

8905 Regents Park Dr., Suite 210, Tampa, FL		33647
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (813) 528-6004

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o	Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)


o	Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)


o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))


o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

{~~A0064935~~A0065646.DOC}

Item 58.0201

~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers~~Events

~~The~~On ~~company~~February ~~CEO~~14, ~~Mr.~~2011 ~~Naren~~Laxai ~~Mallakunta~~Pharma, ~~has~~Ltd. ~~tendered~~(the a“Company”) ~~30-day~~and ~~notice~~one onof ~~December~~its ~~31,~~wholly ~~2010~~owned tosubsidiaries ~~terminate~~OSR ~~his~~Holding ~~services~~Corp. ~~agreement~~filed ~~with~~for ~~the~~bankruptcy ~~company~~protection asunder ~~the~~Chapter ~~company~~11 ~~could~~of ~~not~~the ~~arrive~~Bankruptcy atCode ain ~~mutually~~the ~~agreeable terms with its lenders~~U.S. HeBankruptcy ~~will~~Court befor ~~available~~the toMiddle ~~work~~District ~~with~~of ~~the~~Florida ~~company~~– asTampa aDivision. At ~~consultant~~this ontime ano ~~need~~receiver ~~basis~~has ifbeen ~~required~~appointed byin the ~~company. However~~case, heand ~~will~~ no ~~longer~~order ~~function as Officer/Director~~ of ~~the~~liquidation ~~company~~has ~~with~~been ~~immediate effect~~entered.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Date: January 3, 2011
	Date: February 15, 2011
	LAXAI PHARMA, LTD. (Registrant)
	By:	/s/ ~~Ram~~Murty ~~Ajjarapu~~Azzarapu
		Ram Ajjarapu, Executive Chairman
		Murty Azzarapu, Authorized Officer

{~~A0064935~~A0065646.DOC}

Filing Compare · Laxai Pharma Ltd